Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

The effectiveness and safety of total glucosides of paeony in systemic lupus erythematosus: A systematic review and meta-analysis.

  • 2022-12-16
  • Medicine 101(50)
    • Mengjie Wang
    • Zhiyuan Wang
    • Ying Liu
    • Lei Wang
    • Xiaomeng Wang
    • Ping Jiang

Study Design

Type
Meta-Analysis
Sample size
n = 836
Population
836 patients with systemic lupus erythematosus (SLE)
Methods
Systematic search of multiple databases up to July 2021 for randomized controlled trials of total glucosides of paeony (TGP) combining chemical medicine; meta-analysis using Revman5.3

Background

To evaluate the efficacy and safety of total glucosides of paeony in the treatment of systemic lupus erythematosus (SLE).

Methods

From the creation of the database to July 2021, multiple databases were searched for randomized controlled trials of treating SLE with total glucosides of paeony (TGP) combining chemical medicine. After screening, quality evaluation and data extraction, the included studies were analyzed by Revman5.3 software.

Results

A total of 11 studies were included, including 836 patients (treatment group 417, control group 419). Meta analysis showed that on the basis of routine treatment, TGP could further improve the treatment effective rate (OR = 4.19, 95% CI: 2.21 to 7.95, Z = 4.38, P < .0001), reduced SLE Disease Activity Index (SLEDAI) (MD = -1.70, 95%CI: -2.51 to -0.89, Z = 4.11, P < .0001) and erythrocyte sedimentation rate (MD = -7.04, 95%CI: -8.48 to -5.59, Z = 9.53, P < .00001), reduced the level of immunoglobulin A (IgA) (MD = -0.60, 95%CI: -0.82 to -0.37, Z = 5.24, P < .00001), immunoglobulin G (IgG) (MD = -2.97, 95%CI: -3.72 to -2.23, Z = 7.82, P < .00001), and immunoglobulin M (IgM) (MD = -0.36, 95%CI: -0.45 to -0.27, Z = 7.54, P < .00001), increased the level of complement C3 (MD = 0.34, 95%CI: 0.30 to 0.39, Z = 14.40, P < .00001) and complement C4 (MD = 0.07, 95%CI: 0.06 to 0.08, Z = 10.08, P < .00001), and decreased the recurrence (OR = 0.31, 95%CI: 0.16 to 0.61, Z = 3.39, P = .0007), and there was no significant difference in the incidence of adverse reactions (OR = 0.93, 95%CI: 0.45 to 1.91, Z = 0.20, P = .84).

Conclusion

On the basis of conventional treatment, the combined use of TGP can enhance the clinical efficacy of SLE without increasing the incidence of adverse effects.

Research Insights

Adverse Events Reported

  • Peony→adverse reactions (overall incidence)

    there was no significant difference in the incidence of adverse reactions (OR=0.93, 95%CI: 0.45 to 1.91, Z=0.20, P=.84)

    Finding
    No significant difference
    Magnitude
    OR=0.93, 95% CI: 0.45 to 1.91, Z=0.20, P=.84
    Significant
    No
Back to top